NASAL/ORAL CANNULA SYSTEM - Patent 3247439

(19)

(11)

EP 3 247 439 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	03.03.2021 Bulletin 2021/09

(45)	Mention of the grant of the patent:
	16.12.2020 Bulletin 2020/51

(21)	Application number: 16705616.7

(22)	Date of filing: 22.01.2016

(51)

International Patent Classification (IPC):

A61M 16/06^(2006.01)
A61B 5/08^(2006.01)

A61M 16/08^(2006.01)

(86)	International application number:
	PCT/US2016/014621

(87)	International publication number:
	WO 2016/118922 (28.07.2016 Gazette 2016/30)

(54)	NASAL/ORAL CANNULA SYSTEM NASEN- ODER MUNDKANÜLENSYSTEM SYSTÈME DE CANULE NASALE/BUCCALE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

23.01.2015 US 201562107232 P

(43)	Date of publication of application:
	29.11.2017 Bulletin 2017/48

(73)	Proprietor: Masimo Corporation
	Irvine, CA 92618 (US)

(72)	Inventors:
	ECKERBOM, Anders 182 33 Danderyd (SE) ZYZANSKI, Robert 182 33 Danderyd (SE)

(74)	Representative: Zacco Sweden AB
	Valhallavägen 117 Box 5581 114 85 Stockholm 114 85 Stockholm (SE)

(56)

References cited: :

EP-A1- 1 800 707
WO-A1-2015/121815
US-A1- 2004 045 552
US-A1- 2005 103 347

WO-A1-2012/006415
US-A- 4 989 599
US-A1- 2004 221 846
US-A1- 2014 005 565

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).